Drugs / tividenofusp alfa
tividenofusp alfa
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04251026 | Jul 2020 → Feb 2031 expected | mucopolysaccharidosis type 2 | Denali Therapeutics Inc. | Active not recruiting | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT06075537 | Sep 2023 → Jun 2027 expected | mucopolysaccharidosis type 2 | Denali Therapeutics Inc. | Enrolling by invitation | No outcome recorded |
| Phase 2/3 | NCT05371613 | Jul 2022 → Dec 2027 expected | mucopolysaccharidosis type 2 | Denali Therapeutics Inc. | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tividenofusp alfa | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06075537 ↗ |
| Known as | DNL310 | “This is a multicenter, multiregional, open-label study to assess the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of tividenofusp alfa (DNL310), an investigational...” NCT04251026 ↗1“tividenofusp alfa (DNL310), an investigational central nervous system (CNS)-penetrant enzyme-replacement therapy (ERT)” NCT05371613 ↗ |
| Known as | Etv:ids | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594537 ↗ |
| Modality | Protein / enzyme biologic | “Tividenofusp alfa, comprising iduronate-2-sulfatase fused to an engineered transferrin receptor-binding Fc domain” PMID 41467650 ↗ Jan 2026 |
| Route | Intravenous | “Intravenous repeating dose” NCT04251026 ↗ |